PVLA logo

PALVELLA THERAPEUTICS INC

PVLANASDAQ
πŸ† #1797 by market capEarnings Mar 29 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track PVLA
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.09B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-97.2%
Declining
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
0.4%
Thin
βš–οΈP/S Ratio
51.0x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for PVLA.

Trading Snapshot

Day Range
β€”
52-Week Range
$72.23 – $179.95
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
14.4M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
51.0x
EPS (TTM)
$-4.82
Dividend Yield
β€”
Dilution (1yr)
+405.5%
PVLA logo

PALVELLA THERAPEUTICS INC

PVLA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
89.3%β–Ό βˆ’3.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$39Mβ–² +173.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$25Mβ–² +130.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.3Mβ–² +405.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$57Mβ–Ό βˆ’$26M YoY
StockOtter Β· stockotter.space

About PALVELLA THERAPEUTICS INC

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy7
Buy15
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.